Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors (NCT06493552)
A Modular, Open Label, Randomized Phase II/III Trial to Assess Efficacy of Combining sEphB4-HSA (EphrinB2 Inhibitor) With Immunotherapy Regimens in Patients With EphrinB2-High Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA. The primary objective of this study is to demonstrate additive therapeutic benefit for sEphB4-HSA. The secondary objectives are to determine whether the sEphB4-HSA containing regimen is safe and whether the oncological endpoints of importance in each cohort improve as a result of treatment with sEphB4-HSA containing regimen relative to a predefined threshold or to a control arm in the cohort where available. Treatment continues until progression of disease or unacceptable toxicities arise.
Who can join: Review the eligibility criteria below.
Location: Sarcoma Oncology Center — Santa Monica, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Sarcoma Oncology Center — Santa Monica, California
📞 Contact the Study Coordinator
Phone: (323) 221-7818
Email: info@vasgene.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Muscle-Invasive Bladder Carcinoma
- A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer — Chapel Hill, North Carolina
- Prophylactic Antibiotics in Cystectomy With Diversion — Minneapolis, Minnesota
- Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease — Orlando, Florida
- Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology — Los Angeles, California
- NEO-BLAST: Neoadjuvant Therapy for Bladder Cancer Followed by Active Surveillance vs Treatment — Vancouver, British Columbia
Explore by condition: All Muscle-Invasive Bladder Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.